NR566 Advanced Pharmacology Care of the Family Midterm Review LATEST 2021 – 2022 Chamberlain College
NR 566 / NR566 Advanced Pharmacology Care of the Family Midterm Review| LATEST 2021
/2022 | Chamberlain College
- How to measure the therapeutic effect of HIV therapy
- – RNA LEVELS o baselineo2-4 weeks, no later than 8 weeks every 4-8 weeks until suppressed after suppressed every 3-4 months
- – Long-term virologic suppression x2 years every 6 months
- – any change in status = chemo/steroids every 3 months
- Protease Inhibitor (PIs) Lopinavir – high-risk patients
– ORAL solution: Contraindicated for full-term infants (until 14 days after birth) and premature (until 14 days after due date)
cardiac disease or prolonged QT
3. Protease Inhibitor (PIs) Lopinavir – Lifespan considerations
– Children: Safe after 14 days old
– Pregnancy: approved w/ higher risks
4. Protease Inhibitor (PIs) Lopinavir/ritonavir – adverse effects
– – QT prolongation
- Protease Inhibitor (PIs) Saquinavir – Lifespan considerations
- – Children
Not identified as safe/efficient in children younger than 16 - – Pregnancy
safest PI for pregnancy - – HIV treatment is recommended in pregnancy
- – Children
- Protease Inhibitor (PIs) Saquinavir – adverse reactions
– – QT prolongation
7. Nucleoside/nucleotide Reverse Transcriptase Inhibitors (NRTIs). Didanosine (ddI) – high risk patient
– Increase the risk of pancreatitis with alcohol use, pancreatitis, and IV pentamidine
8. Nucleoside/nucleotide Reverse Transcriptase Inhibitors (NRTIs). Didanosine (ddI) – Lifespan considerations
– Children
approved in 6 years + weighing 20kg
– Pregnancy
less risk
